Furthermore, several properly recognized adverse prognostic markers, which includes U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, missing their negative impact in clients taken care of with VO. The only issue that remained predictive of a shorter development-cost-free survival Within this cohort of clients was TP53 aberrations.112 Finally, the